Effectiveness of referral system for the management of heart failure with tolvaptan

Effectiveness of referral system for the management of heart failure with tolvaptan - Referral system for heart failure with tolvaptan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019675

Enrollment

Registered

2015-11-09

Start date

2015-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congestive heart failure

Interventions

Referral for the initiation of tolvaptan from clinic to hospital

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with congestive heart failure, refractory to the treatment with conventional diuretics

Exclusion criteria

Exclusion criteria: 1. Petients with history of the adverse effects of tolvaptan 2. Patients on dialysis 3. Pregnant women, women who may be pregnant, and breast-feeding women 4. Patients with serum sodium over 145 mEq/L 5. Patients who cannot take medicine orally

Design outcomes

Primary

Measure	Time frame
Scale of signs, symptoms, and parameters of congestion at 6 months after the administration of tolvaptan	—

Secondary

Measure	Time frame
all-cause mortality, cardiovascular mortality, re-admission for heart failure, and chenges in kidney function	—

Countries

Japan

Contacts

Public ContactUemura Yusuke

Anjo Kosei Hospital Cardiovascular Center

yusuke0307@hotmail.com0566-75-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026